Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CANF Can Fite Biofarma

Closed Good Friday 04-17 16:00:00 EDT

1.20

-0.03

-2.44%

盘后1.20

+0.000.00%

19:53 EDT

High1.27	Low1.18	Vol349.49K
Open1.27	D1 Closing1.23	Amplitude7.72%
Mkt Cap15.42M	Tradable Cap12.54M	Total Shares12.85M
T/O427.01K	T/O Rate3.34%	Tradable Shares10.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CANF","market":"US","secType":"STK","nameCN":"Can Fite Biofarma","latestPrice":1.2,"timestamp":1744920000000,"preClose":1.23,"halted":0,"volume":349492,"hourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.2,"latestTime":"19:53 EDT","volume":529,"amount":635.0048,"timestamp":1744933998463},"delay":0,"floatShares":10451666,"shares":12853100,"eps":-1.0863,"marketStatus":"Closed Good Friday","change":-0.03,"latestTime":"04-17 16:00:00 EDT","open":1.27,"high":1.27,"low":1.175,"amount":427006.84420680004,"amplitude":0.077236,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.0863,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":300,"listingDate":1384837200000,"exchange":"AMEX","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.2499,"preClose":1.23,"latestTime":"09:19 EDT","volume":67509,"amount":85161.45584699999,"timestamp":1744895973240},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.2,"latestTime":"19:53 EDT","volume":529,"amount":635.0048,"timestamp":1744933998463},"volumeRatio":0.26976964842009143},"requestUrl":"/m/hq/s/CANF","defaultTab":"news","newsList":[{"id":"2528717381","title":"Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2528717381","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528717381?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:55","pubTimestamp":1744894500,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, April 17, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson.Namodenoson has recently received FDA approval for its first single-patient compassionate use treatment, marking a significant milestone in its clinical journey. This approval has sparked growing interest from oncologists at leading U.S. medical centers, who are now seeking to treat their pancreatic cancer patients with Namodenoson under compassionate use protocols.Can-Fite BioPharma Ltd.   is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/following-fda-compassionate-approval-pancreatic-125500870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","HCC","PK","CANF","BK4139","BK4006"],"gpt_icon":0},{"id":"2527349435","title":"Can Fite Biopharma Ltd : Alliance Global Partners Cuts Target Price to $4.5 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2527349435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527349435?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:22","pubTimestamp":1744716149,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT1B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527090491","title":"Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2527090491","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527090491?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:05","pubTimestamp":1744715155,"startTime":"0","endTime":"0","summary":"Alliance Global Partners analyst James Molloy lowered the firm’s price target on Can-Fite BioPharma (CANF) to $4.50 from $12 and keeps a Buy rating...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-price-target-lowered-to-4-50-from-12-at-alliance-global-partners?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-price-target-lowered-to-4-50-from-12-at-alliance-global-partners?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2527117888","title":"Amex Halt  News Pending Lst 1.595000","url":"https://stock-news.laohu8.com/highlight/detail?id=2527117888","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527117888?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 02:44","pubTimestamp":1744656255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nAQN2KA3DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527124791","title":"Can-Fite BioPharma announces $3.0M registered direct offering of ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527124791","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527124791?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 02:35","pubTimestamp":1744655708,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that it has entered into definitive agreements for the purchase and sale of 2.5M of the company’s American Depo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-3-0m-registered-direct-offering-of-adss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-3-0m-registered-direct-offering-of-adss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2527142311","title":"Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=2527142311","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527142311?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 02:20","pubTimestamp":1744654835,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  said Monday it expects to generate $685 million in projected future revenues from its collaborations.The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.The company said it also expects \"substantial\" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.Price: 1.60, Change: +0.02, Percent Change: +1.59","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CANF"],"gpt_icon":0},{"id":"2527453114","title":"Can-Fite BioPharma trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2527453114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527453114?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 01:40","pubTimestamp":1744652408,"startTime":"0","endTime":"0","summary":"13:39 EDT Can-Fite BioPharma (CANF) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527119832","title":"Amex Halt  News Pending Lst 1.595000","url":"https://stock-news.laohu8.com/highlight/detail?id=2527119832","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527119832?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 01:39","pubTimestamp":1744652378,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nAQN2KA3DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527116890","title":"Can-Fite BioPharma announces completion of analysis of current partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2527116890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527116890?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 20:36","pubTimestamp":1744634172,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced the completion of a comprehensive analysis of its current partnerships and the market potential for its lead dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-completion-of-analysis-of-current-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-announces-completion-of-analysis-of-current-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527169455","title":"Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2527169455","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527169455?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, April 14, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced the completion of a comprehensive analysis of its current partnerships and the market potential for its lead drug candidates, Piclidenoson and Namodenoson upon regulatory approvals.“While we emphasize these figures are derived from our forecasts and subject to inherent uncertainties of drug development and commercialization, we remain highly encouraged by these projections. They underscore the robust strategic foundation that we have built through our diverse collaborations, reflecting both the significant commercial opportunities and potential long-term value we aim to deliver to our shareholders”, stated Can-Fite VP Business Development Dr. Sari Fishman.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-generate-685m-projected-future-123000278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CANF"],"gpt_icon":0},{"id":"2527415206","title":"Can-Fite BioPharma FY24 Net Loss $7.88M","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415206","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415206?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 20:17","pubTimestamp":1744633061,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma FY24 Net Loss $7.88M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44786764/can-fite-biopharma-fy24-net-loss-7-88m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2527154247","title":"Press Release: Can-Fite Reports 2024 Financial Results and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2527154247","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527154247?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 20:00","pubTimestamp":1744632000,"startTime":"0","endTime":"0","summary":"Cancer-Free Survival of 8 Years in Liver Cancer Patient Treated with Namodenoson in Prior Phase II Study. RAMAT GAN, Israel, April 14, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for the year ended December 31, 2024.Pancreatic Cancer - Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration  for the indication of pancreatic cancer, one of the most aggressive malignancies. The designation as an orphan drug will provide, among others, potential for market exclusivity for seven years after approval and several and regulatory advantages  of Namodenoson in this patient population. Recently, the FDA approved compassionate use treatment of a U.S.-based pancreatic cancer patient with its anti-cancer drug Namodenoson.The patent application covers methods of treating obese patients b","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2522057297","title":"bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2522057297","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522057297?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:00","pubTimestamp":1743166800,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc.  and Can-Fite BioPharma Ltd.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 29, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Motti Farbstein, Chief Executive Officer of Can-Fite, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential regulatory and sales milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite believes that it is well positioned for the poten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-fite-biopharma-interviews-130000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","03160","CANF","TV","BK4581","BK4100","BK4099","BIAFW","BK4590","TM","HCC","BK4604","BK4561","BK4006","BK4588","BK4144","ET","AIRI","BIAF","BK4555","BK4187"],"gpt_icon":0},{"id":"2522450887","title":"Can-Fite BioPharma initiates Phase 3 psoriasis study of piclidenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2522450887","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522450887?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 03:48","pubTimestamp":1742932117,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-initiates-phase-3-psoriasis-study-of-piclidenoson?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-initiates-phase-3-psoriasis-study-of-piclidenoson?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2521277627","title":"Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=2521277627","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521277627?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 22:08","pubTimestamp":1742825324,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  said Monday it has initiated a phase 3 study of its Piclidenoson drug candidate in patients with moderate to severe plaque psoriasis, with enrollment starting in Europe and in the US with Canada to follow.The co-primary objectives of the study are the proportion of patients whose psoriasis is reduced in size and severity by 75% or more and the proportion who achieve a Static Physician's Global Assessment score of either 0 or 1 after 16 weeks, the company said.The US Food and Drug Administration encouraged the company to enroll adolescent patients due to the strong safety profile of the drug  demonstrated during development and earlier trials, Can-Fite said.Can-Fite is expecting to file a new drug application for Piclidenoson with the FDA and a marketing authorization plan with the European Medicines Agency on the successful conclusion of the trial, the company said.Price: 1.66, Change: +0.06, Percent Change: +3.94","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","CANF","BK4139"],"gpt_icon":0},{"id":"2520453968","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453968?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:59","pubTimestamp":1742471940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 07:59 ET (11:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF"],"gpt_icon":0},{"id":"2520672921","title":"Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2520672921","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520672921?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 21:23","pubTimestamp":1742304190,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  said Tuesday that the US Food and Drug Administration has approved the compassionate use treatment with anti-cancer drug Namodenoson for a pancreatic cancer patient in the US.The clinical-stage company said it is currently evaluating Namodenoson in a late-stage clinical trial for advanced liver cancer, while it is also testing the drug in a phase 2a pancreatic cancer clinical trial in Israel.The FDA has also granted orphan drug designation to Namodenoson, the company said.Shares of the company rose 12% in recent Tuesday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2520676944","title":"Can-Fite announces FDA approved compassionate use treatment of Namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676944?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:36","pubTimestamp":1742301391,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-announces-fda-approved-compassionate-use-treatment-of-namodenoson?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-announces-fda-approved-compassionate-use-treatment-of-namodenoson?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2520967508","title":"Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2520967508","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520967508?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:30","pubTimestamp":1742301000,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, March 18, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson.Can-Fite BioPharma Ltd.   is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma , a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-fda-approved-compassionate-treatment-123000979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","CANF","BK4006","BK4139"],"gpt_icon":0},{"id":"2516068029","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2516068029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516068029?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:25","pubTimestamp":1741004700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 07:25 ET (12:25 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.canfite.com","stockEarnings":[{"period":"1week","weight":-0.1416},{"period":"1month","weight":-0.4059},{"period":"3month","weight":-0.2258},{"period":"6month","weight":-0.5819},{"period":"1year","weight":-0.3878},{"period":"ytd","weight":-0.2615}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.08289},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.00614},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.067966},{"month":4,"riseRate":0.25,"avgChangeRate":-0.060866},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.022843},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.013576},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.003188},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.030237},{"month":9,"riseRate":0.363636,"avgChangeRate":0.037027},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.04626},{"month":11,"riseRate":0.636364,"avgChangeRate":0.084736},{"month":12,"riseRate":0.25,"avgChangeRate":-0.077538}],"exchange":"AMEX","name":"Can Fite Biofarma","nameEN":"Can Fite Biofarma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Can Fite Biofarma,CANF,Can Fite Biofarma股票,Can Fite Biofarma股票老虎,Can Fite Biofarma股票老虎国际,Can Fite Biofarma行情,Can Fite Biofarma股票行情,Can Fite Biofarma股价,Can Fite Biofarma股市,Can Fite Biofarma股票价格,Can Fite Biofarma股票交易,Can Fite Biofarma股票购买,Can Fite Biofarma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction